MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Cellectar Biosciences Inc

Atidarymo kaina

0.3 3.45

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.28

Max

0.31

Pagrindiniai rodikliai

By Trading Economics

Darbuotojai

11

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+222.58% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-3.4M

10M

Ankstesnė atidarymo kaina

-3.15

Ankstesnė uždarymo kaina

0.3

Cellectar Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-12-11 18:44; UTC

Pagrindinės rinkos jėgos

Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut

Akcijų palyginimas

Kainos pokytis

Cellectar Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

222.58% į viršų

12 mėnesių prognozė

Vidutinis 1 USD  222.58%

Aukščiausias 1 USD

Žemiausias 1 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Cellectar Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

1

Pirkti

1

Laikyti

0

Parduoti

Finansinės naujienos

$

Apie bendrovę Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.